Navitoclax is a senolytic agent that promotes the elimination of senescent cells in cancer and degenerative diseases by targeting prosurvival members of the Bcl2 gene family [31] and is active in senescent embryonic fibroblasts [25]. The gene discussed is BCL2; the disease is cancer.